Stay updated with breaking news from Paradigm Board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
KEY HIGHLIGHTS Primary endpoint relating to synovial fluid biomarkers achieved and positive top-line results reported for the PARA_OA_008 phase 2 clinical...
KEY HIGHLIGHTS Paradigm has been invited to present results from the mucopolysaccharidosis (MPS) program, with an oral presentation at the XVII International...
Key Highlights Paradigm as an NFL Alumni Health corporate member has entered into a research partnership to inform NFL Alumni members about osteoarthritis (OA)...
Key Highlights Paradigm as an NFL Alumni Health corporate member has entered into a research partnership to inform NFL Alumni members about osteoarthritis (OA)...
/PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a clinical-stage biopharmaceutical company focused on repurposing...